Entrada Therapeutics, Inc.

NasdaqGM TRDA

Entrada Therapeutics, Inc. EBIT for the Trailing 12 Months (TTM) ending September 30, 2024: USD 56.88 M

Entrada Therapeutics, Inc. EBIT is USD 56.88 M for the Trailing 12 Months (TTM) ending September 30, 2024, a 265.29% change year over year. EBIT means earnings before interest and taxes, it is calculated as operating income plus non-operating income.

Entrada Therapeutics, Inc. EBIT for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -34.41 M, a 61.81% change year over year.
Entrada Therapeutics, Inc. EBIT for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -90.12 M, a -118.09% change year over year.
Entrada Therapeutics, Inc. EBIT for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -41.32 M.

Key data

Date	EBIT	EBITDA	Net Income	EPS (Diluted)

NasdaqGM: TRDA

Entrada Therapeutics, Inc.

CEO	Mr. Dipal Doshi
IPO Date	Oct. 29, 2021
Location	United States
Headquarters	6 Tide Street
Employees	177
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Key trends

Past 5 years